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Abstract
The FITNET-NHS Trial is a UK, national, trial investigating whether an online cognitive behavioural therapy program
(FITNET-NHS) for treating chronic fatigue syndrome/ME in adolescents is clinically effective and cost-effective in the
NHS. At the time of writing (September 2019), the trial was recruiting participants. This article presents an update to
the planned sample size and data collection duration previously published within the trial protocol.
Trial registration: ISRCTN, ID: 18020851. Registered 8 April 2016.
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Background
The FITNET-NHS Trial is a United Kingdom (UK), na-
tional ,randomised controlled trial testing the acceptabil-
ity, effectiveness and cost-effectiveness of an online
cognitive behavioural therapy (CBT) programme,
FITNET-NHS (Fatigue In Teenagers on the interNET in
the National Health Service), designed to treat adoles-
cents with chronic fatigue syndrome/myalgic encephalo-
myelitis (CFS/ME) [1]. In the UK, most young people
with CFS/ME do not have access to local NHS specialist
medical care for the condition, as there are limited
paediatric CFS/ME specialist centres in the UK. The
FITNET-NHS trial was set up to test the online delivery
of specialist care from one specialist paediatric CFS/ME
site in the south west of England as a means of address-
ing this problem. Recruitment projections were esti-
mated in advance and were based on reaching national
paediatric CFS/ME populations at high volumes – made
possible due to our innovative methodology using en-
tirely remote processes for recruitment and treatment
delivery. The original sample size target if achieved
would have given us sufficient statistical power to detect
a true effect of FITNET-NHS within the subgroup of
participants with co-morbid mood disorder.
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The current article is an amendment to our previously
published protocol for the FITNET-NHS Trial: Baos
et al. (2018) [1].
Amendment
Recruitment into the FITNET-NHS Trial began on 1
November 2016. In mid-2018, it became apparent that
the recruitment rate would not allow us to achieve our
original sample size target (n = 734) without a substantial
extension to the recruitment period. The original sample
size was selected to provide 80% power to detect a 0.4-
standard deviation (SD) difference at 5% significance
with 10% attrition on the primary outcome in a subgroup
of participants (estimated to be 30% or n = 220) with co-
morbid mood disorders of anxiety and depression. For
all participants (with or without co-morbid mood disor-
ders), the original sample size provided 97% power at 1%
significance to detect a 0.35-SD difference on the pri-
mary outcome (Short Form Health Survey; Physical
function Subscale (SF-36-PFS) score) at 6 months.
We reviewed the trial with the funders – National In-
stitute for Health Research, Health Technology Assess-
ment (NIHR HTA, on 10 July 2018) and consulted with
the Trial Management Group (TMG, on 12 September
2018 and 18 October 2018), the Data Safety Monitoring
Committee (DSMC, on 10 October 2018 and by email
report on 11 March 2019) and the Trial Steering Com-
mittee (TSC, on 28 November 2018).
In September 2018, we calculated the required sample
size for the primary outcome in all participants (with or
without co-morbid mood disorders):
Data on 266 children will give us 90% power at 5% sig-
nificance to detect a 0.4-SD difference on the SF-36-PFS.
With attrition currently at approximately 15%, we will
need to recruit 314 children. This is achievable (based
on recruitment rates to date) by the end of October
2020.
This gave us a new recruitment target of 314 children in
total, 157 in each treatment group
We considered the issue of co-morbid disorders. On 2
October 2018, we investigated the rate of co-morbid
mood disorders in FITNET-NHS participants at base-
line. This was higher than our original estimates as the
rate of co-morbid mood disorders was 40% (compared
to 30% in our original estimates). With the revised sam-
ple size target of 314 there will be approximately 106
participants with co-morbid mood disorders (53 in each
treatment group). This will give 53% power at 5% signifi-
cance to detect a 0.4-SD difference on the SF-36-PFS be-
tween treatment groups within this co-morbid subgroup.
From consultation with the NIHR HTA, TSC, DSMC
and TMG, the decision was made to agree revised re-
cruitment targets and extend the recruitment time by 6
months to enable the FITNET-NHS Trial to achieve the
primary aim of testing the effectiveness (and cost-
effectiveness) of the FITNET-NHS treatment compared
to Activity Management. The NIHR HTA gave their ap-
proval in principle of this change on 30 January 2019,
subsequent to provision of documentation. Full NIHR
HTA approval for revised recruitment target and the
contract variation to include the 6-month extension to
the project timeline was received on 24 April 2019. We
will, therefore, recruit 314 children and recruitment will
finish on 31 October 2020. Follow up will finish on 31
October 2021.
We have followed standard procedures to update all
relevant organisations regarding these changes, including
trial registration (ISRCTN, ID: 18020851: change ac-
cepted and records updated on 1 July 2019), and submit-
ting as a substantial trial amendment to the Research
Ethics Committee (REC, approved on 26 July 2019) and
the Health Research Authority (HRA, approved on 10
July 2019).
With our revised recruitment target of 314 partici-
pants, the FITNET-NHS is still set to be the largest
paediatric CFS/ME treatment trial in the UK and glo-
bally, the results of which will should the future of
paediatric CFS/ME treatment delivery.
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